Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：62頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2014’, provides an overview of the Hyperphosphatemia In Chronic Kidney Disease’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hyperphosphatemia In Chronic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hyperphosphatemia In Chronic Kidney Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hyperphosphatemia In Chronic Kidney Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hyperphosphatemia In Chronic Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hyperphosphatemia In Chronic Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hyperphosphatemia In Chronic Kidney Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2014’, provides an overview of the Hyperphosphatemia In Chronic Kidney Disease’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hyperphosphatemia In Chronic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hyperphosphatemia In Chronic Kidney Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hyperphosphatemia In Chronic Kidney Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hyperphosphatemia In Chronic Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hyperphosphatemia In Chronic Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hyperphosphatemia In Chronic Kidney Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hyperphosphatemia In Chronic Kidney Disease Overview 6
Therapeutics Development 7
Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease - Overview 7
Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis 8
Hyperphosphatemia In Chronic Kidney Disease - Therapeutics under Development by Companies 9
Hyperphosphatemia In Chronic Kidney Disease - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Hyperphosphatemia In Chronic Kidney Disease - Products under Development by Companies 13
Hyperphosphatemia In Chronic Kidney Disease - Companies Involved in Therapeutics Development 14
Amgen Inc. 14
Sanofi 15
OPKO Health, Inc. 16
Panion & Bf Biotech Inc. 17
Vifor Pharma AG 18
Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Drug Profiles 27
ferric citrate - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
sucroferric oxyhydroxide - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
bixalomer - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ferric citrate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
fermagate - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
RDX-002 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
VS-501 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
VS-505 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Fe-SAMMS - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Hyperphosphatemia In Chronic Kidney Disease - Recent Pipeline Updates 44
Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects 53
Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products 54
Hyperphosphatemia In Chronic Kidney Disease - Product Development Milestones 55
Featured News & Press Releases 55
Apr 16, 2014: Impax Launches Authorized Generic RENVELA 55
Apr 09, 2014: Keryx Biopharmaceuticals Announces Zerenex Phase 2 Results in Non-Dialysis Dependent Chronic Kidney Disease Selected as a Late Breaking Oral Presentation at the Upcoming National Kidney Foundation 2014 Spring Clinical Meeting 55
Apr 02, 2014: Keryx Biopharmaceuticals Announces EMA Validation of Marketing Authorization Application for Zerenex 56
Mar 10, 2014: Keryx Biopharmaceuticals Announces Submission of a Marketing Authorization Application for Zerenex to the European Medicines Agency 56
Jan 17, 2014: Keryx Biopharmaceuticals Announces Marketing Approval of Ferric Citrate in Japan 57
Nov 28, 2013: Velphoro receives US FDA approval for the treatment of hyperphosphatemia in Chronic Kidney Disease Patients on dialysis 57
Oct 21, 2013: Keryx Biopharmaceuticals Announces PDUFA Goal Date for Zerenex New Drug Application 58
Oct 17, 2013: Keryx Biopharmaceuticals' Zerenex (Ferric Citrate Coordination Complex) Data Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2013 58
Oct 08, 2013: Keryx Biopharmaceuticals Announces FDA Acceptance for Filing of Zerenex New Drug Application 59
Aug 08, 2013: Keryx Biopharmaceuticals Announces New Drug Application Submission for Zerenex for the Treatment of Hyperphosphatemia in Chronic Kidney Disease Patients on Dialysis 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 62
Disclaimer 62
List of Tables
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H1 2014 7
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Amgen Inc., H1 2014 14
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Sanofi, H1 2014 15
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by OPKO Health, Inc., H1 2014 16
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Panion & Bf Biotech Inc., H1 2014 17
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Vifor Pharma AG, H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 21
Number of Products by Stage and Mechanism of Action, H1 2014 23
Number of Products by Stage and Route of Administration, H1 2014 24
Number of Products by Stage and Molecule Type, H1 2014 26
Hyperphosphatemia In Chronic Kidney Disease Therapeutics - Recent Pipeline Updates, H1 2014 44
Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects, H1 2014 53
Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products, H1 2014 54
List of Figures
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H1 2014 7
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Late Stage Products, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 22
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Route of Administration, H1 2014 24
Number of Products by Top 10 Molecule Type, H1 2014 25
Number of Products by Stage and Top 10 Molecule Type, H1 2014 26
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hyperphosphatemia In Chronic Kidney Disease Overview 6
Therapeutics Development 7
Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease - Overview 7
Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis 8
Hyperphosphatemia In Chronic Kidney Disease - Therapeutics under Development by Companies 9
Hyperphosphatemia In Chronic Kidney Disease - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Hyperphosphatemia In Chronic Kidney Disease - Products under Development by Companies 13
Hyperphosphatemia In Chronic Kidney Disease - Companies Involved in Therapeutics Development 14
Amgen Inc. 14
Sanofi 15
OPKO Health, Inc. 16
Panion & Bf Biotech Inc. 17
Vifor Pharma AG 18
Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Drug Profiles 27
ferric citrate - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
sucroferric oxyhydroxide - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
bixalomer - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ferric citrate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
fermagate - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
RDX-002 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
VS-501 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
VS-505 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Fe-SAMMS - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Hyperphosphatemia In Chronic Kidney Disease - Recent Pipeline Updates 44
Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects 53
Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products 54
Hyperphosphatemia In Chronic Kidney Disease - Product Development Milestones 55
Featured News & Press Releases 55
Apr 16, 2014: Impax Launches Authorized Generic RENVELA 55
Apr 09, 2014: Keryx Biopharmaceuticals Announces Zerenex Phase 2 Results in Non-Dialysis Dependent Chronic Kidney Disease Selected as a Late Breaking Oral Presentation at the Upcoming National Kidney Foundation 2014 Spring Clinical Meeting 55
Apr 02, 2014: Keryx Biopharmaceuticals Announces EMA Validation of Marketing Authorization Application for Zerenex 56
Mar 10, 2014: Keryx Biopharmaceuticals Announces Submission of a Marketing Authorization Application for Zerenex to the European Medicines Agency 56
Jan 17, 2014: Keryx Biopharmaceuticals Announces Marketing Approval of Ferric Citrate in Japan 57
Nov 28, 2013: Velphoro receives US FDA approval for the treatment of hyperphosphatemia in Chronic Kidney Disease Patients on dialysis 57
Oct 21, 2013: Keryx Biopharmaceuticals Announces PDUFA Goal Date for Zerenex New Drug Application 58
Oct 17, 2013: Keryx Biopharmaceuticals' Zerenex (Ferric Citrate Coordination Complex) Data Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2013 58
Oct 08, 2013: Keryx Biopharmaceuticals Announces FDA Acceptance for Filing of Zerenex New Drug Application 59
Aug 08, 2013: Keryx Biopharmaceuticals Announces New Drug Application Submission for Zerenex for the Treatment of Hyperphosphatemia in Chronic Kidney Disease Patients on Dialysis 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 62
Disclaimer 62
List of Tables
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H1 2014 7
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Amgen Inc., H1 2014 14
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Sanofi, H1 2014 15
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by OPKO Health, Inc., H1 2014 16
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Panion & Bf Biotech Inc., H1 2014 17
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Vifor Pharma AG, H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 21
Number of Products by Stage and Mechanism of Action, H1 2014 23
Number of Products by Stage and Route of Administration, H1 2014 24
Number of Products by Stage and Molecule Type, H1 2014 26
Hyperphosphatemia In Chronic Kidney Disease Therapeutics - Recent Pipeline Updates, H1 2014 44
Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects, H1 2014 53
Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products, H1 2014 54
List of Figures
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H1 2014 7
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Late Stage Products, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 22
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Route of Administration, H1 2014 24
Number of Products by Top 10 Molecule Type, H1 2014 25
Number of Products by Stage and Top 10 Molecule Type, H1 2014 26
